/PRNewswire/ NYU Langone Health is joining a new National Institutes of Health (NIH)-sponsored program called Accelerating Medicines Partnership Autoimmune.
NYU Langone joins NIH-sponsored program called Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases to find new therapies. Learn more.
NYU Langone Health is joining a new National Institutes of Health (NIH)-sponsored program called Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) as a leading center to discover new targets for therapy in these diseases.
UC San Francisco scientists have formed a research alliance with pharmaceutical firm Eli Lilly and Company aimed at better understanding autoimmune diseases and fostering the development of new therapies. Based on the innovative Immunoprofiler model launched at UCSF in 2017, the new initiative, called AutoImmunoprofiler, inherits the most successful aspects of its predecessor and adapts them to the study of autoimmunity.Â
Autoimmune diseases such as lupus, inflammatory bowel disease, and type 1 diabetes occur when the immune system attacks the bodyâs own tissues. While there are some therapies to treat symptoms of these conditions, the underlying causes are largely unknown. Â Â Â
Matthew âMaxâ Krummel, PhD